The effect of multistage nanovector targeting of VEGFR2 positive tumor endothelia on cell adhesion and local payload accumulation.

[1]  M. Ferrari,et al.  Degradation and biocompatibility of multistage nanovectors in physiological systems. , 2014, Journal of biomedical materials research. Part A.

[2]  Mihue Jang,et al.  Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes. , 2014, Biomaterials.

[3]  W. Freeman,et al.  Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[4]  M. Ferrari,et al.  Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. , 2014, Biomaterials.

[5]  M. Ferrari,et al.  High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. , 2013, ACS nano.

[6]  M. Ferrari,et al.  Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. , 2013, Biomaterials.

[7]  Chen Jiang,et al.  Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. , 2013, Biomaterials.

[8]  M. Ferrari,et al.  Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. , 2013, Cancer letters.

[9]  M. Ferrari,et al.  Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. , 2013, Small.

[10]  M. Ferrari,et al.  Evaluation of cell function upon nanovector internalization. , 2013, Small.

[11]  Mauro Ferrari,et al.  Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery , 2013, Clinical Cancer Research.

[12]  S. Curley,et al.  Remotely triggered cisplatin release from carbon nanocapsules by radiofrequency fields. , 2013, Biomaterials.

[13]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[14]  F. Kratz,et al.  Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Kinam Park,et al.  Analysis on the current status of targeted drug delivery to tumors. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Mauro Ferrari,et al.  Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications , 2012, Chinese science bulletin = Kexue tongbao.

[17]  M. Ferrari,et al.  Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice , 2012, Advanced functional materials.

[18]  Giuseppe Pascazio,et al.  The preferential targeting of the diseased microvasculature by disk-like particles. , 2012, Biomaterials.

[19]  Mauro Ferrari,et al.  Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Mauro Ferrari,et al.  Mesoporous Silicon‐PLGA Composite Microspheres for the Double Controlled Release of Biomolecules for Orthopedic Tissue Engineering , 2012 .

[21]  Mauro Ferrari,et al.  Cooperative, Nanoparticle‐Enabled Thermal Therapy of Breast Cancer , 2012, Advanced healthcare materials.

[22]  Andreas Wicki,et al.  Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth , 2011, Clinical Cancer Research.

[23]  Mauro Ferrari,et al.  Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. , 2011, Accounts of chemical research.

[24]  M. Ferrari,et al.  Site‐Specific Drug Delivery: E‐Selectin‐Targeted Porous Silicon Particle for Nanoparticle Delivery to the Bone Marrow (Adv. Mater. 36/2011) , 2011 .

[25]  Mauro Ferrari,et al.  E‐Selectin‐Targeted Porous Silicon Particle for Nanoparticle Delivery to the Bone Marrow , 2011, Advanced materials.

[26]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[27]  M. Piccart,et al.  Long-term toxic effects of adjuvant chemotherapy in breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Ş. Arslan,et al.  Anti-cancer effect of bee venom in cervical cancer cells: P11.121 , 2011 .

[29]  D. Yoon,et al.  Anti‐cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF‐κB , 2011, The Prostate.

[30]  Mauro Ferrari,et al.  Agarose Surface Coating Influences Intracellular Accumulation and Enhances Payload Stability of a Nano-delivery System , 2011, Pharmaceutical Research.

[31]  Mauro Ferrari,et al.  Near-Infrared Imaging Method for the In Vivo Assessment of the Biodistribution of Nanoporous Silicon Particles , 2011 .

[32]  H. Hanaoka,et al.  Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu‐labeled bevacizumab in colorectal cancer xenografts , 2011, Cancer science.

[33]  Mauro Ferrari,et al.  Near-Infrared Imaging Method for the In Vivo Assessment of the Biodistribution of Nanoporous Silicon Particles , 2011, Molecular imaging.

[34]  Mauro Ferrari,et al.  Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast , 2010, Nature nanotechnology.

[35]  M. Ferrari,et al.  Intracellular trafficking of silicon particles and logic-embedded vectors. , 2010, Nanoscale.

[36]  Mauro Ferrari,et al.  Tailored porous silicon microparticles: fabrication and properties. , 2010, Chemphyschem : a European journal of chemical physics and physical chemistry.

[37]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[38]  R. Tsien,et al.  Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases , 2010, Proceedings of the National Academy of Sciences.

[39]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[40]  V. Yadavalli,et al.  Investigations of chemical modifications of amino-terminated organic films on silicon substrates and controlled protein immobilization. , 2010, Langmuir : the ACS journal of surfaces and colloids.

[41]  Sei-Young Lee,et al.  Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows , 2009, Nanotechnology.

[42]  Mauro Ferrari,et al.  The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. , 2009, Biomaterials.

[43]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[44]  Jennifer S. Park,et al.  Oxidation-triggered release of fluorescent molecules or drugs from mesoporous Si microparticles. , 2008, ACS nano.

[45]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[46]  Mauro Ferrari,et al.  Design maps for nanoparticles targeting the diseased microvasculature. , 2008, Biomaterials.

[47]  N. Ferrara,et al.  VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.

[48]  John C Gore,et al.  Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 Expression Using Targeted Contrast‐Enhanced High‐Frequency Ultrasonography , 2007, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[49]  M Ferrari,et al.  The adhesive strength of non-spherical particles mediated by specific interactions. , 2006, Biomaterials.

[50]  S. Groshen,et al.  Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. , 2006, The Journal of urology.

[51]  V. Lehto,et al.  Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[52]  H. Mehdorn,et al.  Expression of VEGF and its receptors in different brain tumors , 2005, Neurological research.

[53]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[54]  D. Hicklin,et al.  Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. , 2004, Molecular cancer therapeutics.

[55]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[56]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[57]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[58]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[59]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[60]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.